MOREFV · Molecular regulation of blood coagulation factor V: from snakes to humans
FP7 — People (Marie Curie Actions)
- Duration
- 2010-09-01 → 2014-08-31
- EU contribution
- €100,000
- Participants
- 1
- Scheme
- MC-IRG
Lines connect the coordinator with its partners.
Results in brief
Molecular regulation of blood coagulation factor V: from snakes to humans
The blood coagulation response is a uniquely complex process that protects organisms form significant blood loss following vascular damage. A failure of the system to respond at the appropriate time or place can result in life-threatening bleeding disorders, such as hemophilia. In addition to cellular participation, there are numerous proteins involved in the enzymatic reactions that lead to the formation of a blood clot. Most of these enzymes are large complexes consisting of a protease and a cofactor, the latter making the protease much more effective by enhancing its activity several orders of magnitude. These enzymatic complexes assemble on a negatively charged membrane surface, such as that of platelets or endothelial cells. Apart from directing these enzyme complexes to the site of injury, the precise mechanisms by which the membrane surface propagates the coagulation reactions are incomplete. Therefore, the overall goal of this proposal is to provide new information on the molecular mechanisms that regulate the assembly of enzyme-cofactor complexes driving blood coagulation. To do so, we will use a novel strategy based on a naturally occurring variant of a cofactor found in the venom of the Australian common brown snake P. textilis. Strikingly, this cofactor does not require a membrane surface for its enzymatic complex assembly. Using this variant as a model and tool we have generated several panels of snake-human and human-snake chimeras of the blood coagulation cofactor V. In these chimeras we have introduced or removed specific regions that may play a role in the membrane-independent characteristics of snake venom V. Biochemical analysis of these variants revealed that the targeted regions do not play a role in the unique capacity of the snake venom cofactor to function in the absence of lipids. They do suggest, however, that the snake venom enzyme complex functions in a different way altogether as compared to the human enzyme complex, thereby potentially challenging the current paradigm. In addition, these studies have led to novel questions and opened up new avenues of research that are currently being explored. A better understanding of the enzyme complexes that are essential to blood coagulation will provide ground for translational studies aimed at exploring novel therapeutics and targets to restore hemostasis in cases of a deficient (bleeding) or overactive (thrombosis) coagulation system. Mettine H.A. Bos, Ph.D. Assistant Professor Leiden University Medical Center Dept. of Thrombosis and Hemostasis Einthoven Laboratory for Experimental Vascular Medicine Room C7-14 Albinusdreef 2 2333 ZA Leiden The Netherlands Ph: +31 71 526 8133 Email: mbos@lumc.nl Website: http://www.einthovenlaboratory.com/onderzoeken/molecular-regulation-of-blood-coagulation-factor-v-from-snakes-to-humans/
Data: CORDIS, © European Union
Project objective
The overall goal of this proposal is to provide new information on the molecular mechanisms that regulate the cofactor function of blood coagulation factor V (FV). Shedding light on these processes may provide a framework for developing novel strategies for prevention and treatment in cases of disregulation of the blood coagulation response. This is a uniquely complex process that protects organisms from significant blood loss following vascular damage. A failure of this system to respond or to restrict its response can result in life-threatening bleeding disorders or thrombosis. Coagulation FV plays an important role in the clotting system as precursor of FVa, the cofactor for the serine protease FXa that converts prothrombin to thrombin, a key regulatory enzyme in the formation of a blood clot. Interaction of FXa with FVa dramatically enhances its catalytic rate, highlighting the biological significance of FV.Factor Va only interacts with FXa on a phospholipid surface, such as that of platelets or ruptured atherosclerotic plaques. The exact mechanism underlying the membrane-dependence of this interaction is, despite three decades of FV structure-function research, still poorly understood. In the current project, we aim to address this longstanding question using a novel strategy based on a naturally occurring FV variant found in the venom of the Australian snake P.textilis (pt-FV), which has evolved to circumvent the membrane-dependence in FXa binding. We will target several unique structural features of pt-FV that we speculate are involved in its membrane-independent FXa interaction, which will be a) removed from pt-FV and b) introduced into human FV. By characterizing this recombinant FV panel, we anticipate to gain critical insight into the FVa-FXa enzyme complex that is central to coagulation and also into the biology of other macromolecular coagulation complexes, which represents information vital to the engineering of improved therapeutic proteins.
Original text from CORDIS.
Participants
- ACADEMISCH ZIEKENHUIS LEIDEN · LeidenCoordinatorNetherlands
Links
Data: CORDIS, © European Union
